Figure 7. Mechanism of action of Inclisiran for hypercholesterolaemia. Inclisiran, a small interfering RNA (siRNA) with a GalNAc tail, binds to asialoglycoprotein receptors (ASGPR) on hepatocytes, facilitating its uptake. Inside the cell, Inclisiran forms a RISC complex that binds to PCSK9 mRNA, leading to its degradation and reduced PCSK9 production. Lowered PCSK9 levels result in increased LDL receptor recycling and enhanced clearance of LDL from the bloodstream, causing reduction in LDL-C levels. Image created with BioRender. LDL-C, low-density lipoprotein cholesterol.